# Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

> **NCT05715840** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 368 (estimated)

## Conditions studied

- Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

## Interventions

- **DRUG:** SG001 injection
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab injection
- **DRUG:** SG001 placebo

## Key facts

- **NCT ID:** NCT05715840
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-01-31
- **Primary completion:** 2024-07-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 368 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715840, "Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05715840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*